Steve Seedhouse

Stock Analyst at Cantor Fitzgerald

(3.97)

# 579

Out of 5,124 analysts

11

Total ratings

70%

Success rate

10.87%

Average return

Main Sectors:

Top Industries:

Biotechnology Drug Manufacturers - Specialty & Generic

Stocks Rated by Steve Seedhouse

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	WVE Wave Life Sciences	Maintains: Overweight	$12 → $34	$15.15	+124.42%	1	Dec 9, 2025
	BLTE Belite Bio	Assumes: Overweight	$154	$160.18	-3.86%	1	Nov 24, 2025
	KRRO Korro Bio	Downgrades: Neutral	n/a	$8.26	-	1	Nov 13, 2025
	XNCR Xencor	Maintains: Overweight	$40 → $42	$14.06	+198.72%	2	Nov 6, 2025
	INVA Innoviva	Maintains: Overweight	$29 → $31	$19.31	+60.54%	2	Nov 6, 2025
	CAMP Camp4 Therapeutics	Initiates: Overweight	$7	$5.99	+16.86%	1	Oct 2, 2025
	APLS Apellis Pharmaceuticals	Maintains: Overweight	$39 → $40	$23.94	+67.08%	1	Aug 1, 2025
	TVRD Tvardi Therapeutics	Initiates: Overweight	$52	$3.93	+1,223.16%	1	Jul 11, 2025
	HROW Harrow	Initiates: Overweight	$76	$53.50	+42.06%	1	Jul 11, 2025

Wave Life Sciences

Dec 9, 2025

Maintains: Overweight

Price Target: $12 → $34

Current: $15.15

Upside: +124.42%

Belite Bio

Nov 24, 2025

Assumes: Overweight

Price Target: $154

Current: $160.18

Upside: -3.86%

Korro Bio

Nov 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $8.26

Upside: -

Xencor

Nov 6, 2025

Maintains: Overweight

Price Target: $40 → $42

Current: $14.06

Upside: +198.72%

Innoviva

Nov 6, 2025

Maintains: Overweight

Price Target: $29 → $31

Current: $19.31

Upside: +60.54%

Camp4 Therapeutics

Oct 2, 2025

Initiates: Overweight

Price Target: $7

Current: $5.99

Upside: +16.86%

Apellis Pharmaceuticals

Aug 1, 2025

Maintains: Overweight

Price Target: $39 → $40

Current: $23.94

Upside: +67.08%

Tvardi Therapeutics

Jul 11, 2025

Initiates: Overweight

Price Target: $52

Current: $3.93

Upside: +1,223.16%

Harrow

Jul 11, 2025

Initiates: Overweight

Price Target: $76

Current: $53.50

Upside: +42.06%